DiaGen AI
Full site coming soon
Two validated AI platforms for peptide and small-molecule discovery, deployed with clinical, academic, commercial and decentralized partners across four regions.
Platform 01
Small molecules
An atomic-resolution foundation model trained on 6.75M molecules. Flow-network generation explores the chemical space next to a lead compound and returns novel, patentable analogs.
ValidatedDegradation of mutant KRAS-G12D confirmed in cells by the Structural Genomics Consortium at UNC.
Platform 02
Peptides
An end-to-end in silico pipeline — hotspot identification, backbone, sequence, molecular-dynamics validation — that finds the strongest binder among billions of candidates on far less compute.
ValidatedA designed 30-mer held a stable complex with C-reactive protein across a 100-ns MD simulation.
Working with
Partnering & investment
brian@DiaGen.AICompany
www.DiaGen.AIContact
Brian D. Keane, JD — Chairman & CEO